Y-Intercept (HK)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Y-Intercept (HK)’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.04M	Sell	88,599 -127,250	-59%	-$2.08M	0.02%	993
2026 Q2	$4.2M	Buy	215,849 +88,762	+70%	+$1.61M	0.08%	337
2026 Q1	$2.37M	Buy	127,087 +31,115	+32%	+$515K	0.04%	641
2025 Q4	$1.26M	Buy	+95,972	New	+$1.13M	0.03%	865
2025 Q1	–	Sell	-9,229	Closed	-$500K	–	1458
2024 Q4	$500K	Sell	9,229 -11,096	-55%	-$567K	0.03%	726
2024 Q3	$1.02M	Buy	20,325 +7,247	+55%	+$340K	0.06%	440
2024 Q2	$575K	Buy	+13,078	New	+$554K	0.03%	750
2024 Q1	–	Sell	-11,227	Closed	-$678K	–	1611
2023 Q4	$678K	Buy	+11,227	New	+$579K	0.06%	468

Other funds holding MLTX

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

BWM

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Y-Intercept (HK)'s MLTX Position: Q3 2026 in Review

Y-Intercept (HK) reduced its MoonLake Immunotherapeutics (MLTX) stake by 59% in Q3 2026, selling an estimated $2.08M and leaving 88,599 shares worth $1.04M. The position accounts for 0.02% of the portfolio, ranked #993.

Y-Intercept (HK) first reported a position in MLTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $4.2M in Q2 2026. 9 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Y-Intercept (HK) held 88,599 shares of MoonLake Immunotherapeutics worth $1.04M as of Q3 2026.
Y-Intercept (HK) sold 127,250 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $2.08M.
MoonLake Immunotherapeutics made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #993 holding.
Y-Intercept (HK) first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 8 quarters since.
Y-Intercept (HK)'s MoonLake Immunotherapeutics position peaked at $4.2M in Q2 2026.
9 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.